nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2B6—Irinotecan—colon cancer	0.226	0.273	CbGbCtD
Carbinoxamine—CYP2C9—Capecitabine—colon cancer	0.193	0.233	CbGbCtD
Carbinoxamine—CYP2C8—Fluorouracil—colon cancer	0.164	0.198	CbGbCtD
Carbinoxamine—CYP2C9—Fluorouracil—colon cancer	0.114	0.138	CbGbCtD
Carbinoxamine—CYP3A4—Irinotecan—colon cancer	0.0693	0.0838	CbGbCtD
Carbinoxamine—CYP3A4—Vincristine—colon cancer	0.0606	0.0733	CbGbCtD
Carbinoxamine—Chest tightness—Capecitabine—colon cancer	0.00567	0.0328	CcSEcCtD
Carbinoxamine—Neuritis—Vincristine—colon cancer	0.00547	0.0316	CcSEcCtD
Carbinoxamine—Euphoric mood—Fluorouracil—colon cancer	0.00327	0.0189	CcSEcCtD
Carbinoxamine—Extrasystoles—Capecitabine—colon cancer	0.00316	0.0183	CcSEcCtD
Carbinoxamine—Photosensitivity—Fluorouracil—colon cancer	0.00315	0.0182	CcSEcCtD
Carbinoxamine—Chest discomfort—Capecitabine—colon cancer	0.00301	0.0174	CcSEcCtD
Carbinoxamine—Urinary retention—Vincristine—colon cancer	0.00282	0.0163	CcSEcCtD
Carbinoxamine—Irritability—Fluorouracil—colon cancer	0.00264	0.0153	CcSEcCtD
Carbinoxamine—Sweating increased—Irinotecan—colon cancer	0.00243	0.0141	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Vincristine—colon cancer	0.00234	0.0135	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Vincristine—colon cancer	0.00224	0.013	CcSEcCtD
Carbinoxamine—Photosensitivity—Capecitabine—colon cancer	0.0022	0.0127	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Fluorouracil—colon cancer	0.00218	0.0126	CcSEcCtD
Carbinoxamine—Haemolytic anaemia—Capecitabine—colon cancer	0.00214	0.0124	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Fluorouracil—colon cancer	0.00209	0.0121	CcSEcCtD
Carbinoxamine—Agranulocytosis—Fluorouracil—colon cancer	0.00199	0.0115	CcSEcCtD
Carbinoxamine—Diplopia—Capecitabine—colon cancer	0.00193	0.0112	CcSEcCtD
Carbinoxamine—Irritability—Capecitabine—colon cancer	0.00184	0.0107	CcSEcCtD
Carbinoxamine—Urinary retention—Capecitabine—colon cancer	0.00184	0.0106	CcSEcCtD
Carbinoxamine—Chills—Irinotecan—colon cancer	0.00179	0.0104	CcSEcCtD
Carbinoxamine—Agitation—Vincristine—colon cancer	0.00164	0.00949	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—colon cancer	0.00164	0.00948	CcSEcCtD
Carbinoxamine—Sweating increased—Capecitabine—colon cancer	0.00163	0.00941	CcSEcCtD
Carbinoxamine—Vertigo—Vincristine—colon cancer	0.0016	0.00928	CcSEcCtD
Carbinoxamine—Vision blurred—Fluorouracil—colon cancer	0.00157	0.00908	CcSEcCtD
Carbinoxamine—Vertigo—Irinotecan—colon cancer	0.00156	0.00904	CcSEcCtD
Carbinoxamine—Convulsion—Vincristine—colon cancer	0.00155	0.00895	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Capecitabine—colon cancer	0.00152	0.00882	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Capecitabine—colon cancer	0.00146	0.00845	CcSEcCtD
Carbinoxamine—Convulsion—Fluorouracil—colon cancer	0.00144	0.00835	CcSEcCtD
Carbinoxamine—Confusional state—Irinotecan—colon cancer	0.00143	0.00828	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Vincristine—colon cancer	0.00143	0.00825	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Vincristine—colon cancer	0.00141	0.00815	CcSEcCtD
Carbinoxamine—Agranulocytosis—Capecitabine—colon cancer	0.00139	0.00804	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Irinotecan—colon cancer	0.00139	0.00804	CcSEcCtD
Carbinoxamine—Anorexia—Vincristine—colon cancer	0.00139	0.00804	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—colon cancer	0.00137	0.00794	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Irinotecan—colon cancer	0.00137	0.00794	CcSEcCtD
Carbinoxamine—Confusional state—Fluorouracil—colon cancer	0.00137	0.00793	CcSEcCtD
Carbinoxamine—Hypotension—Vincristine—colon cancer	0.00136	0.00788	CcSEcCtD
Carbinoxamine—Anorexia—Irinotecan—colon cancer	0.00135	0.00783	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Fluorouracil—colon cancer	0.00133	0.0077	CcSEcCtD
Carbinoxamine—Tachycardia—Fluorouracil—colon cancer	0.00133	0.00767	CcSEcCtD
Carbinoxamine—Hypotension—Irinotecan—colon cancer	0.00132	0.00767	CcSEcCtD
Carbinoxamine—Insomnia—Vincristine—colon cancer	0.00132	0.00762	CcSEcCtD
Carbinoxamine—Paraesthesia—Vincristine—colon cancer	0.00131	0.00757	CcSEcCtD
Carbinoxamine—Anorexia—Fluorouracil—colon cancer	0.00129	0.0075	CcSEcCtD
Carbinoxamine—Insomnia—Irinotecan—colon cancer	0.00128	0.00743	CcSEcCtD
Carbinoxamine—Paraesthesia—Irinotecan—colon cancer	0.00127	0.00737	CcSEcCtD
Carbinoxamine—Hypotension—Fluorouracil—colon cancer	0.00127	0.00735	CcSEcCtD
Carbinoxamine—Decreased appetite—Vincristine—colon cancer	0.00127	0.00733	CcSEcCtD
Carbinoxamine—Somnolence—Irinotecan—colon cancer	0.00126	0.0073	CcSEcCtD
Carbinoxamine—Fatigue—Vincristine—colon cancer	0.00126	0.00727	CcSEcCtD
Carbinoxamine—Dyspepsia—Irinotecan—colon cancer	0.00125	0.00723	CcSEcCtD
Carbinoxamine—Tinnitus—Capecitabine—colon cancer	0.00125	0.00721	CcSEcCtD
Carbinoxamine—Constipation—Vincristine—colon cancer	0.00124	0.00721	CcSEcCtD
Carbinoxamine—Decreased appetite—Irinotecan—colon cancer	0.00123	0.00714	CcSEcCtD
Carbinoxamine—Insomnia—Fluorouracil—colon cancer	0.00123	0.00711	CcSEcCtD
Carbinoxamine—Fatigue—Irinotecan—colon cancer	0.00122	0.00708	CcSEcCtD
Carbinoxamine—Paraesthesia—Fluorouracil—colon cancer	0.00122	0.00706	CcSEcCtD
Carbinoxamine—Constipation—Irinotecan—colon cancer	0.00121	0.00702	CcSEcCtD
Carbinoxamine—Somnolence—Fluorouracil—colon cancer	0.00121	0.00699	CcSEcCtD
Carbinoxamine—Chills—Capecitabine—colon cancer	0.0012	0.00694	CcSEcCtD
Carbinoxamine—Dyspepsia—Fluorouracil—colon cancer	0.0012	0.00692	CcSEcCtD
Carbinoxamine—Decreased appetite—Fluorouracil—colon cancer	0.00118	0.00684	CcSEcCtD
Carbinoxamine—Feeling abnormal—Irinotecan—colon cancer	0.00117	0.00677	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—colon cancer	0.00113	0.00657	CcSEcCtD
Carbinoxamine—Feeling abnormal—Fluorouracil—colon cancer	0.00112	0.00648	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—colon cancer	0.00111	0.00641	CcSEcCtD
Carbinoxamine—Vision blurred—Capecitabine—colon cancer	0.0011	0.00635	CcSEcCtD
Carbinoxamine—Tremor—Capecitabine—colon cancer	0.00109	0.00631	CcSEcCtD
Carbinoxamine—Urticaria—Fluorouracil—colon cancer	0.00108	0.00625	CcSEcCtD
Carbinoxamine—Vertigo—Capecitabine—colon cancer	0.00104	0.00605	CcSEcCtD
Carbinoxamine—Asthenia—Vincristine—colon cancer	0.00104	0.00605	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—colon cancer	0.00103	0.00599	CcSEcCtD
Carbinoxamine—Palpitations—Capecitabine—colon cancer	0.00103	0.00595	CcSEcCtD
Carbinoxamine—Asthenia—Irinotecan—colon cancer	0.00102	0.00589	CcSEcCtD
Carbinoxamine—Diarrhoea—Vincristine—colon cancer	0.000996	0.00577	CcSEcCtD
Carbinoxamine—Diarrhoea—Irinotecan—colon cancer	0.00097	0.00562	CcSEcCtD
Carbinoxamine—Dizziness—Vincristine—colon cancer	0.000963	0.00557	CcSEcCtD
Carbinoxamine—Confusional state—Capecitabine—colon cancer	0.000957	0.00554	CcSEcCtD
Carbinoxamine—Dizziness—Irinotecan—colon cancer	0.000938	0.00543	CcSEcCtD
Carbinoxamine—Diarrhoea—Fluorouracil—colon cancer	0.000929	0.00538	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Capecitabine—colon cancer	0.000929	0.00538	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—colon cancer	0.000927	0.00537	CcSEcCtD
Carbinoxamine—Tachycardia—Capecitabine—colon cancer	0.000926	0.00536	CcSEcCtD
Carbinoxamine—Vomiting—Vincristine—colon cancer	0.000926	0.00536	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Capecitabine—colon cancer	0.000917	0.00531	CcSEcCtD
Carbinoxamine—Headache—Vincristine—colon cancer	0.000912	0.00528	CcSEcCtD
Carbinoxamine—Anorexia—Capecitabine—colon cancer	0.000904	0.00524	CcSEcCtD
Carbinoxamine—Vomiting—Irinotecan—colon cancer	0.000901	0.00522	CcSEcCtD
Carbinoxamine—Dizziness—Fluorouracil—colon cancer	0.000898	0.0052	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—colon cancer	0.000892	0.00517	CcSEcCtD
Carbinoxamine—Headache—Irinotecan—colon cancer	0.000888	0.00514	CcSEcCtD
Carbinoxamine—Hypotension—Capecitabine—colon cancer	0.000887	0.00513	CcSEcCtD
Carbinoxamine—Nausea—Vincristine—colon cancer	0.000865	0.00501	CcSEcCtD
Carbinoxamine—Vomiting—Fluorouracil—colon cancer	0.000863	0.005	CcSEcCtD
Carbinoxamine—Insomnia—Capecitabine—colon cancer	0.000858	0.00497	CcSEcCtD
Carbinoxamine—Paraesthesia—Capecitabine—colon cancer	0.000852	0.00493	CcSEcCtD
Carbinoxamine—Headache—Fluorouracil—colon cancer	0.000851	0.00493	CcSEcCtD
Carbinoxamine—Nausea—Irinotecan—colon cancer	0.000842	0.00488	CcSEcCtD
Carbinoxamine—Dyspepsia—Capecitabine—colon cancer	0.000835	0.00484	CcSEcCtD
Carbinoxamine—Decreased appetite—Capecitabine—colon cancer	0.000825	0.00478	CcSEcCtD
Carbinoxamine—Fatigue—Capecitabine—colon cancer	0.000818	0.00474	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—colon cancer	0.000816	0.00472	CcSEcCtD
Carbinoxamine—Constipation—Capecitabine—colon cancer	0.000811	0.0047	CcSEcCtD
Carbinoxamine—Nausea—Fluorouracil—colon cancer	0.000807	0.00467	CcSEcCtD
Carbinoxamine—Feeling abnormal—Capecitabine—colon cancer	0.000782	0.00453	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—colon cancer	0.000778	0.0045	CcSEcCtD
Carbinoxamine—Urticaria—Capecitabine—colon cancer	0.000754	0.00437	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—colon cancer	0.00075	0.00434	CcSEcCtD
Carbinoxamine—Confusional state—Methotrexate—colon cancer	0.000712	0.00412	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—colon cancer	0.000692	0.00401	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—colon cancer	0.000683	0.00395	CcSEcCtD
Carbinoxamine—Asthenia—Capecitabine—colon cancer	0.000681	0.00394	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—colon cancer	0.000673	0.0039	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—colon cancer	0.00066	0.00382	CcSEcCtD
Carbinoxamine—Diarrhoea—Capecitabine—colon cancer	0.000649	0.00376	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—colon cancer	0.000639	0.0037	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—colon cancer	0.000634	0.00367	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—colon cancer	0.000628	0.00364	CcSEcCtD
Carbinoxamine—Dizziness—Capecitabine—colon cancer	0.000627	0.00363	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—colon cancer	0.000622	0.0036	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—colon cancer	0.000614	0.00356	CcSEcCtD
Carbinoxamine—Fatigue—Methotrexate—colon cancer	0.000609	0.00353	CcSEcCtD
Carbinoxamine—Vomiting—Capecitabine—colon cancer	0.000603	0.00349	CcSEcCtD
Carbinoxamine—Headache—Capecitabine—colon cancer	0.000594	0.00344	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methotrexate—colon cancer	0.000582	0.00337	CcSEcCtD
Carbinoxamine—Nausea—Capecitabine—colon cancer	0.000564	0.00326	CcSEcCtD
Carbinoxamine—Urticaria—Methotrexate—colon cancer	0.000561	0.00325	CcSEcCtD
Carbinoxamine—Asthenia—Methotrexate—colon cancer	0.000507	0.00293	CcSEcCtD
Carbinoxamine—Diarrhoea—Methotrexate—colon cancer	0.000483	0.0028	CcSEcCtD
Carbinoxamine—Dizziness—Methotrexate—colon cancer	0.000467	0.0027	CcSEcCtD
Carbinoxamine—Vomiting—Methotrexate—colon cancer	0.000449	0.0026	CcSEcCtD
Carbinoxamine—Headache—Methotrexate—colon cancer	0.000443	0.00256	CcSEcCtD
Carbinoxamine—Nausea—Methotrexate—colon cancer	0.00042	0.00243	CcSEcCtD
